Tumour Treating Fields for mesothelioma - Authors' reply

Affiliations

¹ Department of Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy. Electronic address: giovanni_luca.ceresoli@gavazzeni.it.
² Department of Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milano, Italy.
³ Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Comment

Giovanni L Ceresoli et al. Lancet Oncol. 2020 Jan.

. 2020 Jan;21(1):e10.

doi: 10.1016/S1470-2045(19)30831-9.

¹ Department of Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy. Electronic address: giovanni_luca.ceresoli@gavazzeni.it.
² Department of Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milano, Italy.
³ Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Erratum in

Correction to Lancet Oncol 2020; 21: e10.
[No authors listed] [No authors listed] Lancet Oncol. 2020 Feb;21(2):e70. doi: 10.1016/S1470-2045(20)30016-4. Lancet Oncol. 2020. PMID: 32007203 No abstract available.

No abstract available

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F. Ceresoli GL, et al. Lancet Oncol. 2019 Dec;20(12):1702-1709. doi: 10.1016/S1470-2045(19)30532-7. Epub 2019 Oct 15. Lancet Oncol. 2019. PMID: 31628016 Clinical Trial.
Tumour Treating Fields for mesothelioma.
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Barbarino M, et al. Lancet Oncol. 2020 Jan;21(1):e8. doi: 10.1016/S1470-2045(19)30829-0. Lancet Oncol. 2020. PMID: 31908312 No abstract available.
Tumour Treating Fields for mesothelioma.
de Gooijer CJ, Burgers JA. de Gooijer CJ, et al. Lancet Oncol. 2020 Jan;21(1):e9. doi: 10.1016/S1470-2045(19)30828-9. Lancet Oncol. 2020. PMID: 31908313 No abstract available.